Cited by 266SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Open access

Crawford, Katharine H D, Dingens, Adam S, Eguia, Rachel, Wolf, Caitlin R, Wilcox, Naomi, Logue, Jennifer K, Shuey, Kiel, Casto, Amanda M, Fiala, Brooke, Wrenn, Samuel, Pettie, Deleah, King, Neil P, Greninger, Alexander L, Chu, Helen Y, Bloom, Jesse D·2021·The Journal of Infectious Diseases

DOI 10.1093/infdis/jiaa618PMC PMC7543487

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30–152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/infdis/jiaa618

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Change in neutralizing antibody titer over time. A, Neutralizing antibody titer at 50% inhibition (NT50) for each individual in the study, with facets colored according to disease severity (see key below plot). Facet titles indicate sex (F, female; M, male), age, and participant identifier (PID). Dashed blue line indicates the limit of detection for our assay (NT50 = 20). B, Fold change in NT50 compared with 30-day time point, including only individuals with a neutralizing sample at day 30. P values were calculated using the Wilcoxon signed rank test. C, Distribution of NT50 values at the 3 time points, with box plots colored by disease severity and the blue dashed line indicating the limit of detection as in panel A. P values are indicated when there is a significant difference (P ≤ 0.05) between NT50 values for different disease severity categories at a time point and were calculated using the Wilcoxon rank sum test.CC BY · PubMed Central

Figure 2. Immunoglobulin (Ig) A, IgM, and IgG antibody binding titers over time. A, Longitudinal binding antibody titers for each individual as quantified by area under the curve (AUC) of enzyme-linked immunosorbent assays (ELISAs). Facets are arranged by maximal neutralizing antibody titer at 50% inhibition (NT50) from top left to bottom right, as in Figure 1A. Dashed lines indicate the AUC value for the negative control sample (2017–2018 serum sample pool) for each assay, colored by assay. Abbreviations: F, female; M, male; PID, participant identifier; RBD, receptor-binding domain. B, Correlation plots between AUC for each ELISA and neutralization titer (NT50) for all samples. Vertical dashed line indicates the limit of detection for the neutralization assay; horizontal dashed lines, the AUC values for the negative control sample (2017–2018 serum sample pool) for each assay, colored based on the assay as in A. C, For each antibody type measured, individuals who were symptomatic and required hospitalization as part of their care had significantly higher antibody levels during the first 1–2 months after symptom onset. *P ≤ .05; †P ≤ .01. P values were calculated using the Wilcoxon rank sum test. As in A and B, the dashed line in each facet indicates the AUC value for the negative control sample for each assay, colored by assay.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
(2020) · Science · doi:10.1101/2020.07.14.20151126 · Cited by 1,192
IgA dominates the early neutralizing antibody response to SARS-CoV-2
Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd2223 · Cited by 1,037
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822
Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 744
Self-citation
Comprehensive mapping of immune perturbations associated with severe COVID-19
Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd7114 · Cited by 723
SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
Self-citation
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
Self-citation
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho
Bryan, A. B., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00941-20 · Cited by 520
Self-citation
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508
Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint
Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients
Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa721 · Cited by 363
Impaired Antibody-Mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus
Habibi, M. S., Jóźwik, A., Makris, S., Dunning, J. W., Paras, A., DeVincenzo, J. P., de Haan, C. A. M., Wrammert, J., Openshaw, P., & Chiu, C. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2256oc · Cited by 289
Somatically Hypermutated Plasmodium-Specific IgM+ Memory B Cells Are Rapid, Plastic, Early Responders upon Malaria Rechallenge
Krishnamurty, A. T., Thouvenel, C. D., Portugal, S., Keitany, G. J., Kim, K. S., Holder, A. A., Crompton, P. D., Rawlings, D. J., & Pepper, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.014 · Cited by 258
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
Salazar, E., Kuchipudi, S. V., Christensen, P. A., Eagar, T. N., Yi, X., Zhao, P., Jin, Z., Long, S. W., Olsen, R. J., Chen, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141206 · Cited by 216
Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019Preprint
Zhao, J., Yuan, Q., Wang, H., Liu, W. Y., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3546052 · Cited by 208
A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
Dieterle, M. E., Haslwanter, D., Bortz, R. H., Wirchnianski, A. S., Lasso, G., Vergnolle, O., Abbasi, S. A., Fels, J. M., Laudermilch, E., Florez, C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.020 · Cited by 206
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
Beaudoin-Bussières, G., Laumaea, A., Anand, S. P., Prévost, J., Gasser, R., Goyette, G., Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020) · mBio · doi:10.1128/mbio.02590-20 · Cited by 189
Origin and Function of Circulating Plasmablasts during Acute Viral Infections
Fink, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00078 · Cited by 181
IgA dominates the early neutralizing antibody response to SARS-CoV-2Preprint
Sterlin, D., Mathian, A., Miyara, M., et al. (2020) · medRxiv · doi:10.1101/2020.06.10.20126532 · Cited by 175
Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent PatientsPreprint
Wang, X., Guo, X., Xin, Q., et al. (2020) · medRxiv · doi:10.1101/2020.04.15.20065623 · Cited by 171
Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
Temperton, N. J., Chan, P. K. S., Simmons, G., Zambon, M. C. F. A., Tedder, R. S., Takeuchi, Y., & Weiss, R. A. (2005) · Emerging infectious diseases · doi:10.3201/eid1103.040906 · Cited by 157
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
Tai, W., Zhang, X., Drelich, A., Shi, J., Hsu, J. C., Luchsinger, L., Hillyer, C. D., Tseng, C.-T. K., Jiang, S., & Du, L. (2020) · Cell Research · doi:10.1038/s41422-020-0387-5 · Cited by 151
Neutralizing Antibody Response and SARS Severity
Ho, M., Chen, W., Chen, H., Lin, S.-F., Wang, M.-C., Di, J., Lu, Y., Liu, C., Chang, S., Chao, C.-L., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1111.040659 · Cited by 138
The Multifaceted B Cell Response to Influenza Virus
Lam, J. H., & Baumgarth, N. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801208 · Cited by 127
Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections
Lei, Q., Li, Y., Hou, H., Wang, F., Ouyang, Z., Zhang, Y., Lai, D., Ndzouboukou, J. B., Xu, Z., Zhang, B., et al. (2020) · Allergy · doi:10.1111/all.14622 · Cited by 124
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1823890 · Cited by 122
Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform
Chu, H. Y., Englund, J. A., Starita, L. M., Famulare, M., Brandstetter, E., Nickerson, D. A., Rieder, M. J., Adler, A., Lacombe, K., Kim, A. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008646 · Cited by 99
Self-citation
Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies
Arevalo, C. P., Sage, V. L., Bolton, M. J., Eilola, T., Jones, J. E., Kormuth, K. A., Nturibi, E. M., Balmaseda, Á., Gordon, A. L., Lakdawala, S. S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920321117 · Cited by 98
Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak
Dingens, A. S., Crawford, K. H. D., Adler, A., Steele, S. L., Lacombe, K., Eguia, R. T., Amanat, F., Walls, A. C., Wolf, C. R., Murphy, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18178-1 · Cited by 69
Self-citation
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19Preprint
Wu, J., Liang, B., Chen, C., Wang, H., Fang, Y., Shěn, S., Yang, X., Wang, B., Chen, L., Chen, Q., et al. (2020) · medRxiv · doi:10.1101/2020.07.21.20159178 · Cited by 68
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Preprint
Walls, A. C., Fiala, B., Schäfer, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.11.247395 · Cited by 60
Self-citation
Immunologic perturbations in severe COVID-19/SARS-CoV-2 infectionPreprint
Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.18.101717 · Cited by 50
Antibody Dynamics of 2009 Influenza A (H1N1) Virus in Infected Patients and Vaccinated People in China
Wang, M., Yuan, J., Li, T., Liu, Y., Wu, J., Di, B., Chen, X., Xin-hong, X., Lu, E., Li, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016809 · Cited by 44
Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phasesPreprint
Yao, X., Liu, W. Y., Li, Z., Xiong, H., Su, Y., Li, T., Zhang, S., Zhang, X., Bi, Z., Deng, C.-X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-327912/v1 · Cited by 23
Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donorsPreprint
Perreault, J., Tremblay, T., Fournier, M., Drouin, M., Beaudoin-Bussières, G., Prévost, J., Lewin, A., Bégin, P., Finzi, A., & Bazin, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.16.206847 · Cited by 12

Research works printed but not linked: 1

Wu, medRxiv [Preprint]

Sorted by citations

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Self-citation
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
Self-citation

See all 266

Authors: Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., Pettie, D., King, N. P., Greninger, A. L., Chu, H. Y., & Bloom, J. D.
Affiliations: University of Washington (US)
Fred Hutch Cancer Center (US)
Howard Hughes Medical Institute (US)
Corresponding author: Chu, Helen Y
Bloom, Jesse D
ORCID: Crawford, Katharine H D
Dingens, Adam S
Eguia, Rachel
Wolf, Caitlin R
Logue, Jennifer K
Shuey, Kiel
Casto, Amanda M
Fiala, Brooke
Wrenn, Samuel
Pettie, Deleah
King, Neil P
Greninger, Alexander L
Chu, Helen Y
Bloom, Jesse D
Venue: The Journal of Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2020-09-30
Volume: 223
Issue: 2
Pages: 197-205
ISSN: 0022-1899 (ISSN-L)
1537-6613
DOI: 10.1093/infdis/jiaa618
PMC: PMC7543487
OpenAlex: W3091039991
Cited by: 265
References: 53
Citations by year: 2026: 5 · 2025: 13 · 2024: 16 · 2023: 32 · 2022: 58 · 2021: 120 · 2020: 21
FWCI: 7.58
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor, 1 d)
Locations: The Journal of Infectious Diseases (publishedVersion, cc-by)
medRxiv (acceptedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: National Institute of Allergy and Infectious Diseases (R01AI141707, F30AI149928)
National Institutes of Health
Bill and Melinda Gates Foundation (OPP1156262)
Burroughs Wellcome Fund
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody titer decline, spike protein, receptor binding domain, humoral immune response, long-term immunity, asymptomatic infection
MeSH terms: COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Female, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks